



Dr. Francesco Zappa

Kontakt

Dr. Francesco Zappa
Switzerland

Publikationen (5)

Baty F, Jörger M, Früh M, Klingbiel D, Zappa F, Brutsche M. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. *J Transl Med* 2017; 15:66.

Baty F, Klingbiel D, Zappa F, Brutsche M. High-throughput alternative splicing detection using dually constrained correspondence analysis (DCCA). *J Biomed Inform* 2015

Franzini A, Zappa F, Klingbiel D, Grigoriu B, Betticher D, Droege C, Oliver D, Macovei I, Baty F, Brutsche M. Gene expression signatures predictive of bevacizumab/erlotinib therapeutic benefit in advanced non-squamous non-small cell lung cancer patients (SAKK 19/05 trial). *Clin Cancer Res* 2015

Baty F, Brutsche M, Pless M, Zappa F, Crowe S, Bubendorf L, Gautschi O, Rauch D, Cathomas R, Dröge C, Betticher D, Früh M, Rothschild S, Swiss Group for Clinical Cancer Research. EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. *PloS one* 2013; 8:e72966.

Gautschi O, Stahel R, Carbone D, Na K, Hsu Schmitz S, Bubendorf L, Baty F, Brutsche M, Pless M, Zappa F, Roder J, Grigorieva J, Roder H, Peters S, Crowe S, Dingemans A, Smit E. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. *Lung Cancer* 2012; 79:59-64.

Projekte (1)

Circulating micro-RNA profiling in patients with advanced non-squamous non small-cell lung cancer receiving bevacizumab/erlotinib first-line treatment followed by platinum-based chemotherapy at disease progression (SAKK 19/05)

Grundlagenforschung - 01.04.2012 - 01.09.2013

Abgeschlossen

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch